# New Migraine Treatment Guidelines Are Here—This Is What Doctors Want You to Know
The American Academy of Neurology and the American Headache Society have released updated migraine treatment guidelines, marking the first comprehensive update in over a decade. These new recommendations reshape how neurologists and primary care doctors approach migraine management, from prevention to acute treatment.
The guidelines emphasize a personalized medicine approach rather than one-size-fits-all treatment. Doctors now prioritize matching medications to individual patient characteristics, lifestyle factors, and migraine patterns. This shift reflects growing evidence that effectiveness varies widely between patients, even for the same drug class.
For acute migraine treatment, the guidelines reinforce triptans as first-line therapy for patients with moderate to severe headaches. However, they now place equal weight on newer options like gepants and lasmiditan. These newer classes work through different mechanisms than triptans, offering alternatives for patients who don't tolerate older medications or who experience cardiovascular concerns that might restrict triptan use.
The prevention recommendations carry particular weight. The guidelines now recommend considering preventive medication for patients experiencing four or more migraine days monthly, down from the previous threshold of eight days. This lower threshold acknowledges research showing that earlier intervention reduces disability and improves quality of life. Preventive options now explicitly include CGRP monoclonal antibodies like erenumab (Aimovig), fremanezumab (Ajovy), and eptinezumab (Vyepti), which have shown strong efficacy in clinical trials.
Botulinum toxin injections remain the only FDA-approved preventive for chronic migraine, defined as 15 or more headache days monthly. The guidelines affirm its role while noting it requires specialist administration.
Lifestyle modifications anchor all treatment recommendations. The guidelines stress addressing identified triggers like sleep disruption, stress, hormonal fluctuations, and dietary factors. They recommend regular aerobic exercise, stress management techniques, and consistent sleep schedules as foundational strategies that complement medication.
The new parameters also spotlight the importance of tracking and communication. Keeping a migraine diary helps patients and doctors identify patterns and evaluate treatment response objectively. This data collection becomes especially valuable when trying new medications or preventive strategies.
Notably, the guidelines recommend against certain older practices. Combination analgesics and opioids no longer receive endorsement for migraine treatment due to overuse and medication overuse headache risks. This represents a significant shift from historical practice patterns.
Patients should bring these updated guidelines to their next healthcare appointment. If your current treatment approach hasn't produced meaningful relief, discuss whether a medication change or preventive strategy aligns with these new recommendations. Doctors who haven't updated their migraine protocols may still rely on older frameworks.
The guidelines also address special populations. Women of childbearing age can now access clear guidance on medication safety during pregnancy and breastfeeding. Older adults have specific recommendations accounting for potential drug interactions and age-related physiology changes.
Access represents an ongoing challenge. While these medications exist, insurance coverage, cost, and specialist availability remain barriers for many patients. Advocacy for better access to newer preventive options continues as an important public health goal.